thank you for viewing this presentation

Thank you for viewing this presentation.

We would like to remind you that this material is the property of the author.

It is provided to you by the ERS for your personal use only, as submitted by the

author.

2010 by the author

2

MDR- and XDR-TB:prevention, treatment and control

J-P Zellweger

ERS/TB PAN NET ToT, Barcelona 2010

3

Objectives• To familiarise with the new documents available on

MDR- and XDR-TB management and with the specific components of the Stop TB Strategy

• To analyse the main findings on drug resistance trends, improvement of laboratory services and treatment delivery process, and the actions undertaken to tackle MDR- and XDR- TB

• To identify priorities and proposed solutions to further prevent the emergence of drug resistance and improve the management of MDR- and XDR- TB

4

Causes of DR

5

Guidelines for the programmatic management of drug-resistant tuberculosis (1)

1 Background information on DR-TB2 Framework for effective control of DR-TB3 Political commitment and coordination 4 Definitions: case registration, bacteriology and treatment

outcomes5 Case-finding strategies 6 Laboratory aspects 7 Treatment strategies for MDR-TB and XDR-TB 8 Mono- and poly-resistant strains9 Treatment of DR-TB in special conditions and situations10 DR-TB and HIV infection 11 Initial evaluation, monitoring of treatment and management of

adverse effects

6

Guidelines for the programmatic management of drug-resistant tuberculosis (2)

12 Treatment delivery and community-based DR-TB support 13 Management of patients with MDR-TB treatment failure14 Management of contacts of MDR-TB patients15 Drug resistance and infection control 16 Human resources: training and staffing17 Management of second-line antituberculosis drugs 18 Category IV recording and reporting system19 Managing DR-TN through patient-centered careANNEX 1 Drug information sheetsANNEX 2 Weight-based dosing of drugs for adultsANNEX 3 Suggestions for further readingANNEX 4 Legislation, human rights, and patient’s right in TB

care prevention and control ANNEX 5 Use of experimental drugs outside of clinical trials ANNEX 5 Methodology

7

New STB strategy and Update on XDR epidemiology

8

9

10

11

12

13

14

DOTS MDR-TB

FUNDING: Government Commitment (10$/ case)

> money

Up to 20,000 $/ caseDIAGNOSIS: SS microscopy, QA and safety measures

+C, DST, SRL, QA, infection control

TREATMENT: SCC,DOT, 6-8 months, no hospitalization

24 months, mandatory DOT & hospitalization in reference facilities

TB drugs only, no AE relevant toxicity, need special drugs + expertise

TREATMENT MONITORING: SS, standard outcome definitions

C, DST, special outcome definitons

15

Who needs DST?

• Cat I, II failures, chronics• Failure anti-TB TX in the private sector• Contacts of DR-/MDR-TB• HCW at risk, prisoners, homeless, etc.• No SS/C conversion Month 2,3• Residence in very high DR-prevalence settings• Exposure to poor quality drugs• Previous treatment by poor programmes• Co-morbidities favouring rapid transit/ malabsorbtion• HIV+ • If available: for ALL TB patients!

16

Algorithm for rapid DST testing

17

DST testing in routine conditions

18

19

How to design a regimen for MDR-TB cases

20

21

22

23

24

25

26

27

28

29

30

XDR= extensively drug-resistant TB

Definition

Resistance to at least rifampicin and isoniazid, in addition to any fluoroquinolone, and to at least one of the three following injectable drugs used in anti-TB treatment: capreomycin, kanamycin and amikacin.

31

What was known

• Operational definition, proposed without solid evidence

• SRLs’ survey on XDR-TB isolates (“ a posteriori”, no outcomes)

• Anecdotal description of virtually untreatable TB patients

32

What was not known on XDR?

• Is the risk of death/ probability of success different from that of MDR?

• Are their clinical characteristics different? in HIV-negative patients?

• Is their infectiousness different?• Has the XDR definition a clinical relevance?

Which is the role of susceptibility to first-line drugs different from HR?

33

ERS and TBNET studies contributed to answer

• Time to SS and C conversion double than MDR-TB• Risk of death 5.5 times higher• Higher failure and default rates than MDR-TB• Lower success rate than MDR-TB• High proportion of adverse events due to 2°-line TB

drugs• XDR-TB definition has both clinical and operational

significance

Migliori GB et al, ERJ 2007Sotgiu et al, ERJ 2008

34

Global Policy: MDR-TB and XDR-TB

1. Strengthen basic TB control, to prevent M/XDR-TB2. Scale-up programmatic management and care of

MDR-TB and XDR-TB 3. Strengthen laboratory services for adequate and

timely diagnosis of MDR-TB and XDR-TB4. Ensure availability of quality drugs and their

rational use5. Expand MDR-TB and XDR-TB surveillance 6. Introduce infection control, especially in high HIV

prevalence settings7. Mobilize urgently resources domestically and

internationally8. Promote research and development into new

diagnostics, drugs and vaccines

Conclusions• MDR/XDTR-TB is one of the major threats for

the future control of TB

• MDR/XDR-TB is basically a man-made problem

• The main issues are:– Stopping the source: control of all ERRORS which

sustain the creation of new cases– Accessing second-line drugs– Managing medical, human and economical

problems associated with the treatment

35